August 20, 2009 (FinancialWire) — MAKO Surgical Corp. (NASDAQ: MAKO), a medical device company that markets both its RIO(r) Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS(r) implants for minimally invasive orthopedic knee procedures known as MAKOplasty(r), has closed its public offering of 8,050,000 shares of its common stock, which includes 1,050,000 shares issued as a result of the underwriters’ exercise of their over-allotment option.

Piper Jaffray & Co. acted as the sole book-running manager for the offering and Leerink Swann LLC acted as co-manager.

MAKO plans to use the net proceeds of approximately $54.4 million, after deducting underwriting discounts and commissions and estimated expenses of the offering, to support commercialization, sales, marketing and general administrative activities, for research and product development activities and to fund working capital and other general corporate purposes.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.